NasdaqGS:STOKBiotechs
Why Stoke Therapeutics (STOK) Is Down 11.4% After NEJM Data on Dravet Syndrome Drug - And What's Next
In March 2026, Stoke Therapeutics and Biogen reported New England Journal of Medicine data showing that investigational antisense therapy zorevunersen produced substantial, durable seizure reductions and multi-year cognitive and behavioral improvements in children and adolescents with Dravet syndrome on top of standard anti-seizure medicines, with an overall safety profile the companies describe as generally well tolerated.
The publication is important because it presents multi-year...